Overview

A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma

Status:
Not yet recruiting

Trial end date:
2023-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to observe and evaluate the efficacy and safety of SHR-1210 for adjuvant treatment of resectable esophageal squamous cell carcinoma

Phase:

Phase 2

Details

Lead Sponsor:

The First Affiliated Hospital of Zhengzhou University